Verve Therapeutics Acquisition Marks New Chapter in Gene Editing
Published on 11/15/2025 at 15:31 | Redaktion boerse-global.de
The independent journey of Verve Therapeutics on public markets concluded on July 25, 2025, when the biotechnology firm was officially delisted from the Nasdaq. This move resulted from its comprehensive acquisition by pharmaceutical leader Eli Lilly, terminating Verve’s status as a publicly traded entity.
Eli Lilly secured ownership of all outstanding Verve shares through a transaction valuing each share at up to $13.50. The arrangement includes an immediate cash payment of $10.50 per share, supplemented by a contingent value right potentially delivering an additional $3.00 per share. With the total deal value potentially reaching $1.3 billion, this acquisition represents a significant consolidation within the biopharmaceutical sector.
Revolutionary Cardiovascular Treatment Drives Interest
The Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
